Xultophy and Soliqua Will Be the First Basal Insulin/GLP-1 Agonist Combos

Xultophy (ZUL-toh-fye) and Soliqua (soh-LEE-kwa) will be two new once-daily injectables for type 2 diabetes.

These meds are the first basal insulin/GLP-1 agonist combos.

Xultophy combines insulin degludec (Tresiba) and liraglutide (Victoza) into a single injection...and Soliqua combines insulin glargine (Lantus, etc) plus lixisenatide (Adlyxine).

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote